Trial Outcomes & Findings for Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS (NCT NCT00887679)
NCT ID: NCT00887679
Last Updated: 2014-10-31
Results Overview
The HAM-A is administered by an interviewer who asks a series of questions related to symptoms of anxiety. The interviewer then rates the individual on a five-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining seven items address somatic anxiety. The total anxiety score ranges from 0 to 56, lower scores are better. Change from randomization to end of treatment in scores on the Hamilton Anxiety Rating Scale (HAM-A)is measured.
COMPLETED
PHASE3
30 participants
baseline and 7 weeks
2014-10-31
Participant Flow
Anxiety disorders in HIV-infected patients from the general population
Participant milestones
| Measure |
Escitalopram
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.
|
|---|---|
|
Overall Study
STARTED
|
30
|
|
Overall Study
COMPLETED
|
20
|
|
Overall Study
NOT COMPLETED
|
10
|
Reasons for withdrawal
| Measure |
Escitalopram
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.
|
|---|---|
|
Overall Study
Withdrawal by Subject
|
1
|
|
Overall Study
Lost to Follow-up
|
4
|
|
Overall Study
Physician Decision
|
5
|
Baseline Characteristics
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
Baseline characteristics by cohort
| Measure |
Escitalopram
n=30 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
30 Participants
n=99 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
|
Age, Continuous
|
43.6 years
STANDARD_DEVIATION 8.12 • n=99 Participants
|
|
Sex: Female, Male
Female
|
10 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
20 Participants
n=99 Participants
|
|
Region of Enrollment
United States
|
30 participants
n=99 Participants
|
PRIMARY outcome
Timeframe: baseline and 7 weeksPopulation: 3 patients dropped out, 4 patients did not met the criteria, and 3 patients did not show up.
The HAM-A is administered by an interviewer who asks a series of questions related to symptoms of anxiety. The interviewer then rates the individual on a five-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining seven items address somatic anxiety. The total anxiety score ranges from 0 to 56, lower scores are better. Change from randomization to end of treatment in scores on the Hamilton Anxiety Rating Scale (HAM-A)is measured.
Outcome measures
| Measure |
Escitalopram
n=20 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Subjects received escitalopram 10-20mg. Escitalopram was started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day.
|
|---|---|
|
Change From Randomization to End of Treatment in Scores on the Hamilton Anxiety Rating Scale (HAM-A)
|
21.23 scores on an anxiety scale
Standard Deviation 2.57
|
PRIMARY outcome
Timeframe: baseline and 7 weeksScoring The BDI consist of twenty-one questions about how the subject has been feeling in the last week. Each question has a set of at least four possible answer choices, ranging in intensity as follows: (0) I do not feel sad. 1. I feel sad. 2. I am sad all the time and I can't snap out of it. 3. I am so sad or unhappy that I can't stand it. A value of 0 to 3 is assigned for each answer and the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows:\[6\] 0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. Higher total scores indicate more severe depressive symptoms.
Outcome measures
| Measure |
Escitalopram
n=20 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Subjects received escitalopram 10-20mg. Escitalopram was started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day.
|
|---|---|
|
Changes From Randomization to End of Treatment in Scores on the Beck Depression Inventory
|
27.8 units on a scale
Standard Deviation 7.89
|
SECONDARY outcome
Timeframe: baseline and 7 weeksPopulation: 3 patients dropped out, 4 patients did not meet criteria, and 3 patients did not show up.
Scale for scoring: Clinical Global Impression(CGI-S) 1. = Normal, no symptoms 2. = Borderline ill 3. = Mildly ill 4. = Moderately ill 5. = Markedly ill 6. = Severely ill 7. = Most extremely ill Clinical Global Impression(CGI-I)-improvement since treatment 1. very much improved 2. much improved 3. minimally improved 4. no change from baseline 5. minimally worse 6. much worse 7. very much worse
Outcome measures
| Measure |
Escitalopram
n=20 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Subjects received escitalopram 10-20mg. Escitalopram was started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day.
|
|---|---|
|
Change From Randomization to End of Treatment in Scores for the Clinical Global Impression(CGI-S and CGI-I)
Clinical Global Impression (CGI-I)
|
1 scores on a scale
Standard Deviation 0.0
|
|
Change From Randomization to End of Treatment in Scores for the Clinical Global Impression(CGI-S and CGI-I)
Clinical Global Impression (CGI-S)
|
2 scores on a scale
Standard Deviation 1.0
|
SECONDARY outcome
Timeframe: baseline to 7 weeksTrail Making Test (TMT)Results for TMT are reported as the number of seconds required to complete the task. Higher scores reveal greater impairment. Average =29 seconds, Deficient \> 78 seconds
Outcome measures
| Measure |
Escitalopram
n=20 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Subjects received escitalopram 10-20mg. Escitalopram was started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day.
|
|---|---|
|
Change From Randomization to End of Treatment for Trail Making Tet (TMT)
|
29.2 seconds
Standard Deviation 11.23
|
SECONDARY outcome
Timeframe: baseline and 7 weeksMini Mental State Examination (MMSE),a low score less than or equal to 23 indicates cognitive impairment and the need for further evaluation; normal cognitive function = 27-30, mild cognitive impairment = 21-26, moderate cognitive impairment = 11-20, and severe cognitive impairment = 0-10. The highest possible score is 30.
Outcome measures
| Measure |
Escitalopram
n=20 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Subjects received escitalopram 10-20mg. Escitalopram was started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day.
|
|---|---|
|
Changes From Randomization to End of Treatment in Scores on the Mini Mental State Examination (MMSE)
|
0 units on a scale
Standard Deviation 0
|
SECONDARY outcome
Timeframe: baseline and 7 weeksScoring: Participants rate the extent to which work, social life, and home life are impaired by his or her symptoms. A 10 point scale is used where 0= not impaired and 10 is highly impaired indicating. The three aspects of life can be summed up into a single dimensional measure of global functional impairment that indicates 0= not impaired and 30 = highly impaired. Scores of 5 or greater are on any of the three scales are considered significant.
Outcome measures
| Measure |
Escitalopram
n=20 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Subjects received escitalopram 10-20mg. Escitalopram was started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day.
|
|---|---|
|
Changes From Randomization to End of Treatment in Scores on the Sheehan Disability Scores (SDS)
|
0 units on a scale
Standard Deviation 0
|
Adverse Events
Escitalopram
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Escitalopram
n=30 participants at risk
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.
|
|---|---|
|
Gastrointestinal disorders
nause
|
23.3%
7/30
|
|
Nervous system disorders
dizziness
|
13.3%
4/30
|
|
Gastrointestinal disorders
diarrhea
|
10.0%
3/30
|
|
Gastrointestinal disorders
dry mouth
|
13.3%
4/30
|
|
Nervous system disorders
headache
|
3.3%
1/30
|
|
Gastrointestinal disorders
constipation
|
6.7%
2/30
|
Additional Information
Dr. Ashwin A Patkar Associate Professor
Duke University Medical Center
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place